Why Is Moderna (MRNA) Stock Price Up 14.36% Today, Aug 25? Melanoma Vaccine Repricing and Fair Value Hikes Extend Post-Trial Rally

Moderna shares extended a sharp post-trial rerating after positive Phase 3 melanoma vaccine results with Merck's Keytruda, reinforcing the market narrative that oncology could become a second platform beyond respiratory vaccines. No fresh Aug. 25 catalyst was identified, suggesting positioning and valuation resets drove the move. Elevated momentum and wide intraday ranges imply continued sensitivity to profit-taking and upcoming clinical, regulatory, and commercialization details.